Base de dados : MEDLINE
Pesquisa : E02.774.945.500.500 [Categoria DeCS]
Referências encontradas : 807 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 81 ir para página                         

  1 / 807 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457374
[Au] Autor:Pecoraro Y; Carillo C; Diso D; Mantovani S; Cimino G; De Giacomo T; Troiani P; Shafii M; Gherzi L; Amore D; Rendina EA; Venuta F; Anile M
[Ad] Endereço:Department of Thoracic Surgery, Policlinico Umberto I, Sapienza University of Rome, Italy. Electronic address: ylenia.pecoraro@uniroma1.it.
[Ti] Título:Efficacy of Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome After Lung Transplantation.
[So] Source:Transplant Proc;49(4):695-698, 2017 May.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Lung transplantation (LT) is only therapeutic option for patients affected by chronic respiratory failure. Chronic rejection, also known as bronchiolitis obliterans syndrome (BOS), is still the main cause of death and the most important factor that influences post-transplantation quality of life. Currently available therapies have not been proven to result in significant benefit in the prevention or treatment of BOS. Extracorporeal photopheresis (ECP) seems to reduce the rate of lung function decline in transplant recipients with progressive BOS. METHODS: From 1991 until now, 239 LTs were performed at our center. Fifty-four patients (22.5%) developed BOS; 15 of these (27.7%) were treated with ECP. At the beginning of the treatment, all patients showed a mean decline of forced expiratory volume in 1 second (FEV ) from baseline values of 45.8% ± 17.2%; 2 patients were in long-term oxygen therapy. RESULTS: Mean follow-up from November 2013 to June 2016 was 11.6 ± 7 months. Twelve patients (80%) showed lung function stabilization with an FEV range after treatment between -6% to +8% from the pre-treatment values. We did not report any adverse effects or increase of infections incidence. DISCUSSION: ECP seems to be an effective and well-tolerated therapeutic option for LT patients with BOS in terms of stabilization of lung function and increased survival.
[Mh] Termos MeSH primário: Bronquiolite Obliterante/etiologia
Bronquiolite Obliterante/terapia
Rejeição de Enxerto/terapia
Transplante de Pulmão/efeitos adversos
Fotoferese/métodos
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171212
[Lr] Data última revisão:
171212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  2 / 807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28640721
[Au] Autor:Rushton C; Goodgrove R; Robertson L; Taylor T; Taylor P; Alfred A
[Ad] Endereço:Specialist Nurse in Photopheresis, The Rotherham NHS Foundation Trust.
[Ti] Título:The introduction and evaluation of a pressure ulcer risk assessment tool for photopheresis outpatients.
[So] Source:Br J Nurs;26(12 Suppl):S16-S22, 2017 Jun 22.
[Is] ISSN:0966-0461
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Chronic graft-versus-host disease (cGVHD) patients are at high risk of compromised skin integrity, and of developing pressure ulcers, which may bleed and/or become infected. The Rotherham Outpatient Screening Tool (ROST) was adapted from the Waterlow score and the Malnutrition Universial Screening Tool (MUST) to suit patients attending an outpatient unit for photopheresis. A review of the screening tool highlighted patients at a higher risk of developing pressure damage during treatment and therefore the unit was able to reduce this risk by the provision of a pressure-relieving cushion (Repose).
[Mh] Termos MeSH primário: Doença Enxerto-Hospedeiro/terapia
Fotoferese/métodos
Lesão por Pressão/prevenção & controle
[Mh] Termos MeSH secundário: Assistência Ambulatorial
Doença Crônica
Doença Enxerto-Hospedeiro/complicações
Seres Humanos
Projetos Piloto
Lesão por Pressão/enfermagem
Estudos Retrospectivos
Medição de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170829
[Lr] Data última revisão:
170829
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170623
[St] Status:MEDLINE
[do] DOI:10.12968/bjon.2017.26.12.S16


  3 / 807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28495794
[Au] Autor:Martin PJ; Storer BE; Inamoto Y; Flowers MED; Carpenter PA; Pidala J; Palmer J; Arora M; Jagasia M; Arai S; Cutler CS; Lee SJ
[Ad] Endereço:Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA.
[Ti] Título:An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.
[So] Source:Blood;130(3):360-367, 2017 Jul 20.
[Is] ISSN:1528-0020
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:No gold standard has been established as a primary endpoint in trials of initial treatment of chronic graft-versus-host disease (GVHD), and evidence showing the association of any proposed primary endpoint with clinical benefit has not been conclusively demonstrated. To address this gap, we analyzed outcomes in a cohort of 328 patients enrolled in a prospective, multicenter, observational study within 3 months after diagnosis of chronic GVHD. Complete and partial response, stable disease, and progressive disease were defined according to the 2014 National Institutes of Health Consensus Development Conference on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease. Success was defined as complete or partial response with no secondary systemic treatment or recurrent malignancy at 1 year after enrollment. Success was observed in fewer than 20% of the patients. The burden of disease manifestations at 1 year was lower for patients in this category than for those with stable or progressive disease. Systemic treatment ended earlier, and subsequent mortality was lower among patients with complete or partial response than among those with stable or progressive disease and those who had received secondary systemic treatment. We conclude that survival with a complete or partial response and no previous secondary systemic treatment or recurrent malignancy at 1 year after initial systemic therapy is associated with clinical benefit, a critical characteristic for consideration as a primary endpoint in a pivotal clinical trial. This prospective observational study was registered at www.clinicaltrials.gov as #NCT00637689.
[Mh] Termos MeSH primário: Determinação de Ponto Final
Doença Enxerto-Hospedeiro/prevenção & controle
Neoplasias Hematológicas/terapia
Transplante de Células-Tronco Hematopoéticas
Imunossupressores/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Inibidores de Calcineurina/uso terapêutico
Doença Crônica
Progressão da Doença
Feminino
Doença Enxerto-Hospedeiro/diagnóstico
Doença Enxerto-Hospedeiro/imunologia
Doença Enxerto-Hospedeiro/mortalidade
Neoplasias Hematológicas/imunologia
Neoplasias Hematológicas/mortalidade
Neoplasias Hematológicas/patologia
Seres Humanos
Masculino
Meia-Idade
Fotoferese
Prednisona/uso terapêutico
Estudos Prospectivos
Recidiva
Rituximab/uso terapêutico
Índice de Gravidade de Doença
Sirolimo/uso terapêutico
Análise de Sobrevida
Condicionamento Pré-Transplante
Transplante Homólogo
Estados Unidos
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Calcineurin Inhibitors); 0 (Immunosuppressive Agents); 4F4X42SYQ6 (Rituximab); VB0R961HZT (Prednisone); W36ZG6FT64 (Sirolimus)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170816
[Lr] Data última revisão:
170816
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170513
[St] Status:MEDLINE
[do] DOI:10.1182/blood-2017-03-775767


  4 / 807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28410041
[Au] Autor:Rushton C; Robertson L; Taylor T; Taylor P; Alfred A
[Ad] Endereço:Specialist Nurse in Photopheresis, The Rotherham NHS Foundation Trust.
[Ti] Título:Implementation and evaluation of a pre-assessment telephone triage system in an outpatient photopheresis service.
[So] Source:Br J Nurs;26(7):400-404, 2017 Apr 13.
[Is] ISSN:0966-0461
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The prompt assessment of patients as fit for photopheresis is imperative to ensure delivery of a safe and efficient service. Before January 2015 the photopheresis unit was reliant on patients contacting the department directly to cancel their appointment if they were unwell or were suffering from any pre-defined exclusion criteria. Methods to reduce the number of cancellations and patients arriving unwell were therefore examined. The authors combined aspects of patient pre-assessment with telephone triage to develop a system that could provide better care and improve the use of resources within the department. The pre-assessment telephone triage system successfully reduced cancellations and increased patient awareness of conditions that would prevent delivery of photopheresis treatment. Subsequently the quality improvement initiative established that the pre-assessment telephone triage system saved the photopheresis unit over £33 000 over a 12-month period.
[Mh] Termos MeSH primário: Assistência Ambulatorial
Fotoferese
Telefone
Triagem/métodos
[Mh] Termos MeSH secundário: Seres Humanos
Estudos Retrospectivos
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:170415
[St] Status:MEDLINE
[do] DOI:10.12968/bjon.2017.26.7.400


  5 / 807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28271523
[Au] Autor:Liu C; Schindler E; LeRoy M; Martin-Bredahl K; Dino M; Shah K; Dynis M; Eby CS; Grossman BJ
[Ad] Endereço:Department of Pathology & Immunology, Washington University, Saint Louis, MO, USA.
[Ti] Título:Safety and collection efficiency with a lower transfusion threshold for extracorporeal photopheresis in adult patients with graft-versus-host disease.
[So] Source:Vox Sang;112(4):379-387, 2017 May.
[Is] ISSN:1423-0410
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Extracorporeal photopheresis (ECP) is an established treatment for graft-versus-host disease (GVHD). Various haematocrit thresholds have been used to trigger red blood cells transfusion prior to ECP. Moderate-to-severe GVHD is frequently complicated by anaemia; the safety and collection efficiency with a lower haematocrit for ECP is unknown. METHODS: We prospectively enrolled 26 consecutive adult GVHD patients with haematocrits between 25% and 28·9% who received ECP on the CELLEX system. Preprocedural transfusion was withheld. We monitored the adverse events and transfusions avoided. A complete blood cell count with differential was performed on preprocedural peripheral blood and buffy coat collected. Lymphocyte fold enrichment (LFE) was compared between this cohort and two historical control groups with haematocrits of 29% or higher. RESULTS: Red Blood Cells transfusion was avoided in the lower-haematocrit cohort without adverse events. The median LFE was 4·5 (95%CI, 3·1-5·7) in the lower-haematocrit cohort and 5·2 (95%CI, 4·1-6·5) in the higher-haematocrit CELLEX-treated control group. The median difference was 0·7 (95%CI, -0·3 to 2·0, P = 0·14). It could not be established that the lower-haematocrit cohort was non-inferior to the higher-haematocrit control group with a prespecified non-inferiority margin of 1·3. However, LFE was significantly higher in the lower-haematocrit cohort than the higher-haematocrit UVAR XTS-treated control group (P < 0·01). CONCLUSION: Buffy coat can be collected for ECP using CELLEX in GVHD patients with a haematocrit of 25% or higher, with a collection efficiency superior to that in patients with higher haematocrits but treated using UVAR XTS. No increase in adverse events was observed at these lower haematocrits.
[Mh] Termos MeSH primário: Segurança do Sangue
Transfusão de Eritrócitos
Doença Enxerto-Hospedeiro/terapia
Fotoferese
[Mh] Termos MeSH secundário: Adulto
Feminino
Doença Enxerto-Hospedeiro/sangue
Hematócrito
Seres Humanos
Masculino
Meia-Idade
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170309
[St] Status:MEDLINE
[do] DOI:10.1111/vox.12504


  6 / 807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28220931
[Au] Autor:Alfred A; Taylor PC; Dignan F; El-Ghariani K; Griffin J; Gennery AR; Bonney D; Das-Gupta E; Lawson S; Malladi RK; Douglas KW; Maher T; Guest J; Hartlett L; Fisher AJ; Child F; Scarisbrick JJ
[Ad] Endereço:Rotherham Foundation NHS Trust, Rotherham, UK.
[Ti] Título:The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.
[So] Source:Br J Haematol;177(2):287-310, 2017 Apr.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of erythrodermic cutaneous T-cell lymphoma (CTCL) and over 20 years for chronic and acute graft-versus-host disease (GvHD) and solid organ transplant rejection. ECP for CTCL and GvHD is available at specialised centres across the UK. The lack of prospective randomised trials in ECP led to the development of UK Consensus Statements for patient selection, treatment schedules, monitoring protocols and patient assessment criteria for ECP. The recent literature has been reviewed and considered when writing this update. Most notably, the national transition from the UVAR XTS machine to the new CELLEX machine for ECP with dual access and a shorter treatment time has led to relevant changes in these schedules. This consensus statement updates the previous statement from 2007 on the treatment of CTCL and GvHD with ECP using evidence based medicine and best medical practise and includes guidelines for both children and adults.
[Mh] Termos MeSH primário: Rejeição de Enxerto/terapia
Doença Enxerto-Hospedeiro/terapia
Linfoma Cutâneo de Células T/terapia
Fotoferese/métodos
[Mh] Termos MeSH secundário: Consenso
Seres Humanos
Reino Unido
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14537


  7 / 807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28094112
[Au] Autor:Del Fante C; Perotti C
[Ad] Endereço:Immunohaematology and Transfusion Service, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100, Italy. Electronic address: c.delfante@smatteo.pv.it.
[Ti] Título:Extracorporeal photopheresis for bronchiolitis obliterans syndrome after allogeneic stem cell transplant: An emerging therapeutic approach?
[So] Source:Transfus Apher Sci;56(1):17-19, 2017 Feb.
[Is] ISSN:1473-0502
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Bronchiolitis obliterans syndrome (BOS) is the main manifestation of pulmonary GVHD. It has often a dramatic and fast evolution and current treatment (change or increase in immunosuppression, macrolides and inhaled therapy) is poor with high mortality rates. In this scenario, extracorporeal photopheresis (ECP) bursts as a new immunomodulatory approach with a different philosophical purpose. In fact, available data show that ECP treatment is intended to delay the inflammatory process and consequently respiratory lung function decline, rather than reverse the damage itself. Preliminary results reported in literature show that ECP may effectively improve/slow lung function decline in cGVHD patients with BOS after standard treatment failure. Further studies are needed to confirm the efficacy of ECP, assess the optimal schedule and consider it for early treatment.
[Mh] Termos MeSH primário: Bronquiolite Obliterante/fisiopatologia
Doença Enxerto-Hospedeiro/terapia
Transplante de Pulmão/métodos
Fotoferese/métodos
Transplante Homólogo/métodos
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170724
[Lr] Data última revisão:
170724
[Sb] Subgrupo de revista:T
[Da] Data de entrada para processamento:170118
[St] Status:MEDLINE


  8 / 807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28039955
[Au] Autor:Coelho R; Hanna R; Flagg A; Stempak LM; Ondrejka S; Procop GW; Harrington S; Zembillas A; Kusick K; Gonzalez BE
[Ad] Endereço:Center for Pediatric Infectious Diseases, Cleveland Clinic Children's Hospital, Cleveland, OH, USA.
[Ti] Título:Mycobacterium genavense-induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literature.
[So] Source:Transpl Infect Dis;19(2), 2017 Apr.
[Is] ISSN:1399-3062
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:We describe the first reported pediatric patient to our knowledge with a spindle cell pseudotumor caused by Mycobacterium genavense in a hematopoietic stem cell transplant recipient, and review the literature of such an entity in the transplant population.
[Mh] Termos MeSH primário: Doença Enxerto-Hospedeiro/terapia
Transplante de Células-Tronco Hematopoéticas/efeitos adversos
Histiócitos/microbiologia
Imunossupressores/efeitos adversos
Linfonodos/microbiologia
Infecções por Micobactéria não Tuberculosa/microbiologia
Micobactérias não Tuberculosas/patogenicidade
Condicionamento Pré-Transplante/efeitos adversos
[Mh] Termos MeSH secundário: Abdome
Adolescente
Alemtuzumab
Antibioticoprofilaxia
Antibióticos Antituberculose/uso terapêutico
Anticorpos Monoclonais Humanizados/efeitos adversos
Anticorpos Monoclonais Humanizados/uso terapêutico
Transplante de Medula Óssea/efeitos adversos
Líquido da Lavagem Broncoalveolar/microbiologia
Ciclosporina/efeitos adversos
Ciclosporina/uso terapêutico
Diabetes Mellitus Tipo 1/congênito
Diabetes Mellitus Tipo 1/cirurgia
Diarreia/cirurgia
Doenças Genéticas Ligadas ao Cromossomo X/cirurgia
Rejeição de Enxerto/cirurgia
Seres Humanos
Doenças do Sistema Imune/congênito
Doenças do Sistema Imune/cirurgia
Imunossupressores/uso terapêutico
Linfonodos/patologia
Masculino
Melfalan/efeitos adversos
Melfalan/uso terapêutico
Infecções por Micobactéria não Tuberculosa/tratamento farmacológico
Infecções por Micobactéria não Tuberculosa/patologia
Ácido Micofenólico/efeitos adversos
Ácido Micofenólico/uso terapêutico
Micobactérias não Tuberculosas/isolamento & purificação
Fotoferese
Reação em Cadeia da Polimerase
Condicionamento Pré-Transplante/métodos
Vidarabina/efeitos adversos
Vidarabina/análogos & derivados
Vidarabina/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibiotics, Antitubercular); 0 (Antibodies, Monoclonal, Humanized); 0 (Immunosuppressive Agents); 3A189DH42V (Alemtuzumab); 83HN0GTJ6D (Cyclosporine); FA2DM6879K (Vidarabine); HU9DX48N0T (Mycophenolic Acid); P2K93U8740 (fludarabine); Q41OR9510P (Melphalan)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170101
[St] Status:MEDLINE
[do] DOI:10.1111/tid.12656


  9 / 807 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27976780
[Au] Autor:Hähnel V; Dormann F; Nitsopoulos A; Friedle A; Ahrens N
[Ad] Endereço:Institute for Clinical Chemistry and Laboratory Medicine, Transfusion Medicine, University Hospital Regensburg, Franz-Josef-Strauss-Allee 11, 93053 Regensburg, Germany. norbert.ahrens@ukr.de.
[Ti] Título:A method for the quantification of 8-methoxypsoralen by mass spectrometry for offline extracorporeal photopheresis.
[So] Source:Photochem Photobiol Sci;16(2):193-200, 2017 02 15.
[Is] ISSN:1474-9092
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Extracorporeal photopheresis (ECP) is an efficient method to treat various autoimmune diseases, cutaneous T-cell lymphoma, and graft-versus-host disease. It is based on the ex vivo inactivation of lymphocytes by 8-methoxypsoralen (8-MOP)/UV light treatment. Despite the adhesive, lipophilic nature of 8-MOP, no quality control is established for the ECP procedure. METHODS: We developed a sensitive high-performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) assay to monitor residual 8-MOP concentration after UVA irradiation in the whole blood supernatant after acetonitrile precipitation. RESULTS: The preanalytical stability of 8-MOP exceeded 7 days, allowing batch mode analysis. Linearity was determined with R above 0.99. The 8-MOP concentrations decreased exponentially after UV exposure, with decay constants of 0.0259 in plasma and 0.0528 in saline. The recovery of 8-MOP in photopheresates was about 68%, indicating binding to DNA as well as to plastic structures. UVA induced no 8-MOP fragmentation, but caused self-adducts under extreme conditions (10-fold UV dosage). CONCLUSIONS: Detection of 8-MOP proved to be feasible and demonstrated that the doses were in the pharmaceutically active range.
[Mh] Termos MeSH primário: Análise Química do Sangue/métodos
Metoxaleno/análise
Fotoferese
Fármacos Fotossensibilizantes/análise
Espectrometria de Massas em Tandem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Cromatografia Líquida de Alta Pressão
Feminino
Cromatografia Gasosa-Espectrometria de Massas
Seres Humanos
Linfócitos/efeitos dos fármacos
Linfócitos/metabolismo
Linfócitos/efeitos da radiação
Masculino
Meia-Idade
Raios Ultravioleta
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Photosensitizing Agents); U4VJ29L7BQ (Methoxsalen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161216
[St] Status:MEDLINE
[do] DOI:10.1039/c6pp00327c


  10 / 807 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27658806
[Au] Autor:Kavand S; Lehman JS; Hashmi S; Gibson LE; El-Azhary RA
[Ad] Endereço:Department of Medicine, Presence Saint Francis Hospital, University of Illinois, Evanston, IL, USA.
[Ti] Título:Cutaneous manifestations of graft-versus-host disease: role of the dermatologist.
[So] Source:Int J Dermatol;56(2):131-140, 2017 Feb.
[Is] ISSN:1365-4632
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Graft-versus-host disease (GVHD) is the major complication of hematopoietic stem cell transplantation and is associated with high mortality in severe cases. The skin is one of the major organs affected in both acute and chronic GVHD. This review aims to elucidate the basic characteristics of GVHD, and the role and contribution of dermatologists in the care of patients with this condition.
[Mh] Termos MeSH primário: Dermatologia
Doença Enxerto-Hospedeiro/diagnóstico
Doença Enxerto-Hospedeiro/terapia
Papel do Médico
Dermatopatias/diagnóstico
Dermatopatias/terapia
[Mh] Termos MeSH secundário: Doença Aguda
Inibidores de Calcineurina/uso terapêutico
Doença Crônica
Doença Enxerto-Hospedeiro/etiologia
Transplante de Células-Tronco Hematopoéticas/efeitos adversos
Seres Humanos
Imunoglobulinas Intravenosas/uso terapêutico
Terapia PUVA
Fotoferese
Fatores de Risco
Dermatopatias/etiologia
Esteroides/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Calcineurin Inhibitors); 0 (Immunoglobulins, Intravenous); 0 (Steroids)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160924
[St] Status:MEDLINE
[do] DOI:10.1111/ijd.13381



página 1 de 81 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde